How Relevant Were the Models Used to Measure the Impact of Panton-Valentine Leukocidin in Human Staphylococcal Infections?
To the Editor-Voyich et al. [1] reported findings that led them to assert " [PVL] is not the major determinant of disease caused by these prominent CA-MRSA strains" (p. 1769). The 3 lines of evidence supporting this assertion contain enough methodological uncertainties to make such a conclusive statement premature at best.
First are the limitations inherent in the murine sepsis model, especially when applied to the issue at hand. Mouse leukocytes are not lysed by Panton-Valentine leukocidin (PVL) as they are in rabbits and humans. Also, in the mouse sepsis model, mice are relatively resistant to intravenous bacterial challenges, which necessitates the use of high concentrations over relatively short periods of time [2, 3] . The immediate response to bacterial cell-wall constituents in this model is likely to obscure the contributions of secreted toxins.
Second, in the murine and rabbit abscess models, according to Voyich et al., direct inoculations of up to or- 7 1 ϫ 10 ganisms produced abscesses in 4 days that resolved on their own in 2 weeks. The difference between this picture and the rapid evolution ("spider bites" or necrotizing fasciitis) seen in human infections, which are caused by much smaller inocula, raises as many questions about the animal models as they do about the contribution of PVL. Toxin production or secretion may be down-regulated under conditions of high bacterial density or other environmental factors [4] .
Third, the results of in vitro leukocyte lysis experiments, which used isogenic dpvl strains of USA300 and USA400 and conditioned cell-culture medium, raise more questions than they answer, particularly given that they seem to contradict previous observations in human leukocytes, demonstrating pore formation, down-regulation of oxidative burst, and binding to mitochondrial membranes by the intact toxin in vitro [5] . Failure to demonstrate differences in pore formation or cell lysis after phagocytosis in cell culture is an interesting observation that may be related to PVL regulation during these host-cell interactions. After all, the authors' postphagocytosis polymerase chain reaction data indicate a much lower up-regulation of PVL transcripts, compared with that of other lytic enzymes measured under their cell-culture conditions-a fact that is not mitigated by the demonstration that immunoreactive toxin molecules are produced under more favorable culture conditions. Far from diminishing the relevance of PVL in these infections, their data may only indicate that they have chosen animal models and culture conditions that are insufficient to study its effects in humans. On the other hand, we disagree with Kernodle's argument that our study was inadequate. Key details of our study and many published studies are at variance with his hypothesis and were overlooked. First, the role played by a-toxin in CA-MRSA virulence remains to be determined, given that the strains used by Patel et al. [5] were neither CA-MRSA nor related to such phylogenetic lineages. Notably, the in vivo end points of the S. aureus infection models used in our study were different from those used by Patel et al. This is because the work by Patel et al. used mouse intraperitoneal inoculation rather than intravenous infection, and they measured skin lesions 24 h after subcutaneous inoculation rather than abscesses, which typically take several days to develop fully in mice [3, 6] . The lesions described by Patel et al. are characteristic of those preceding dermonecrosis [3, 6] , a phenomenon known to be associated with a-toxin (and observed with strain LAC but not MW2). In addition, that study used an inoculum of S. aureus at least 5 times that used in our study to achieve a similar lethal effect [3, 5] .
Second, Kernodle's idea relating to atoxin-neutralizing humoral immunity and lack of preexisting immunity to PVL is speculation and is at variance with published studies [7] . Studies by Lack and Towers [7] demonstrated that only 48% of individuals with confirmed S. aureus infections have high titers of anti-a-toxin antibody, compared with the 70% who have high titers of anti-PVL antibody. According to Lack and Towers, "anti-leucocidin levels rose more consistently than anti-a-haemolysin" (p. 1229) [7] . Inasmuch as the LukS components of g-hemolysin and PVL are 77% identical [8] (see comparisons of the published sequences in MW2), the high levels of anti-PVL antibody might be due, in part, to cross-reactivity of the anti-Hlg antibody, which is known to occur at relatively high titers in humans [9] . In any case, a significant population of individuals lack
